IKNA News and Press, Ikena Oncology Inc.

2024-05-29 14:38:54 ET More on Mid-day movers & stock Faraday Future Intelligent Electric, Inc. (FFIE) Q4 2023 Earnings Call Transcript Why AST SpaceMobile's Q1 2024 Results Just Squeezed Short-Sellers AST SpaceMobile, Inc. (ASTS) Q1 2024 Earnings Call Transcript...

2024-05-29 14:22:11 ET More on Ikena Oncology Ikena to cut workforce by 53%, explore strategic options (update) Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...

2024-05-29 10:00:15 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-28 16:47:06 ET More on Ikena Oncology Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology Read the full article on Seeking Alpha For further details see: ...

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...

2024-05-14 10:59:49 ET More on Ikena Oncology Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology Read the full article on Seeking Alpha For further details see: ...

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2...

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...